Skip to main content

Table 1 Patient characteristics at baseline, N = 53

From: Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study

Patient characteristic Median (IQR) or n (%)
Age, years 49.0 (38.0–55.0)
Female, n 41.0 (77.4%)
Last known EDSS scorea 2.0 (1.5–3.3)
Time since diagnosis, yearsb 6.5 (3.0–12.0)
Duration of therapy, monthsc 47.0 (30.8–96.3)
Duration of therapy with sc IFN β-1a, months 24.0 (20.0–36.0)
Patients with relapse during past 9 months, n 8.0 (15.1%)
  1. EDSS expanded disability status scale, IFN interferon, IQR interquartile range expressed as Q1–Q3, sc subcutaneous
  2. aData missing for 2 patients
  3. bData missing for 1 patient
  4. cData missing for 5 patients